



**New York State Medicaid Drug Utilization Review (DUR) Board Meeting
Room 3, Concourse Level, Empire State Plaza, Albany NY
May 15, 2025
10:00am to 4:00pm**

The meeting will be available for public viewing as a live and archived webcast
[Department of Health Events and Webcasts](#)

10:00 – 10:15 Welcome and Introductions

10:15 – 11:45 Public Comment Period

11:45 – 12:45 Preferred Drug Program (PDP) Review

The DUR Board will review the therapeutic classes listed below, as they pertain to the PDP ([NYS Public Health Law, Sections 272 and 273](#)), and recommend drugs for preferred or non-preferred status. The review may also include revisions to clinical criteria or coverage parameters within the therapeutic class. The Preferred Drug List (PDL), which includes preferred or non-preferred status and clinical criteria, may be viewed at: [NYRx Preferred Drug List](#). For therapeutic classes currently subject to the PDP, the DUR Board will only consider clinical information, which is new since the previous review of the therapeutic class and then consider financial information.

1. Anti-Virals – Oral
Previous Review Date: 6/15/2012
2. Beta Blockers
Previous Review Date: 6/27/2013
Drug(s) to be added to the therapeutic class: Hemangeol (propranolol)
3. Antimigraine Agents – Other
Previous Review Date: 9/21/2023
4. Antipsychotics – Second Generation
Previous Review Date: 9/21/2023
5. Sedative Hypnotics / Sleep Agents
Previous Review Date: 4/22/2015
6. Glucagon Agents
Previous Review Date: 5/18/2023
7. Insulin – Rapid-Acting
Previous Review Date: 9/17/2015



-
8. Colony Stimulating Factors
Previous Review Date: 5/13/2021
 9. Hemophilia Agents – Other
Initial Review
 10. Platelet Inhibitors
Previous Review: 4/27/2017
 11. Prostaglandin Agonists – Ophthalmic
Previous Review Date: 9/20/2018
Drug(s) to be added to the therapeutic class: Rhopressa (netarsudil)
 12. Alpha Reductase Inhibitors for BPH
Previous Review Date: 6/27/2013
 13. Urinary Tract Antispasmodics
Previous Review Date: 5/18/2023
 14. COPD Agents
Previous Review Date: 5/18/2023

12:45 – 2:45 Lunch / Executive Session (PDP Financial Review)

2:45 – 3:15 PDP Recommendations

3:15 – 3:45 Drug Utilization Review

1. The DUR Board will review the following drugs / drug categories that may be dispensed without a prescription (i.e. over-the-counter drugs that are dispensed with a fiscal order) and, if applicable, recommend coverage changes:
 - a. Dermatological agents
 - Aluminum chloride

3:45 – 4:00 Final Comments and Adjournment

The agenda timeline is subject to change based on meeting proceedings.

Additional Information

Parties interested in providing public comments during the DUR Board meeting must complete the registration process by May 7, 2025. Requests to provide public comment may be made by calling 518-486-3209 or e-mailing dur@health.ny.gov (please reference May DUR Board Meeting Speaker Request).



Public comments are limited to items on the agenda. Comments must be brief (2 minutes), and the total comment period will not exceed ninety (90) minutes. The Department of Health (DOH) reserves the right to limit the number of interested parties providing public comment to meet agenda timelines and accomplish meeting objectives.

Written statements and clinical information can be sent to dur@health.ny.gov. Any studies cited should be referenced, with the primary source of funding included.

Written statements should summarize key points and may not exceed two (2) pages in length. Written statements must be received by May 7, 2025. Any other clinical information must be received by April 30, 2025.

All information must be sent to the DOH. Interested parties should not contact or send any information directly to DUR Board members.

DUR Board Members may participate by [videoconferencing from a non-public location under extraordinary circumstances](#) if an unexpected factor or event precludes physical attendance.

Other Meeting Locations

University at Buffalo School of Pharmacy and Pharmaceutical Sciences
Abbott Hall Room 130
Buffalo, NY 14214

SUNY Global Center
Boardroom
116 East 55th Street, New York, NY 10022